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Abstract
Background& Aims—The goal of radiofrequency ablation (RFA) for patients with Barrett’s
esophagus (BE) is to eliminate dysplasia and metaplasia. The efficacy and safety of RFA for
patients with BE and neoplasia are incompletely characterized.
Methods—We performed a retrospective study of 244 patients treated with RFA for BE with
dysplasia or intramucosal carcinoma. Efficacy outcomes were complete eradication of intestinal
metaplasia (CEIM), complete eradication of dysplasia (CED), total treatments, and RFA sessions.
Safety outcomes included death, perforation, stricture, bleeding, and hospitalization. We identified
factors associated with incomplete EIM and stricture formation.
Results—CEIM was achieved in 80% of the patients, and CED in 87%; disease progressed in 4
patients. A higher percentage of patients with incomplete EIM were female (40%) than those with
CEIM (20%, P=.045); patients with incomplete EIM also had a longer segment of BE (5.5 vs 4.0
cm, P=.03), incomplete healing between treatment sessions (45% vs 15%, P=0.004), and
underwent more treatment sessions (4 vs 3, P=.007). Incomplete healing was independently
associated with incomplete EIM. Twenty-three patients (9.4%) had a treatment-related
complication during 777 treatment sessions (3.0%), including strictures (8.2%), post-procedural
hemorrhages (1.6%), and hospitalizations (1.6%). Patients that developed strictures were more
likely to use non-steroidal anti-inflammatory drugs (NSAID) than those without strictures (70% vs
45%, P=.04), have undergone antireflux surgery (15% vs 3%, P=.04), or had erosive esophagitis
(35% vs 12%, P=.01).
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Conclusions—RFA is highly effective and safe for treatment of BE with dysplasia or early-
stage cancer. Strictures were the most common complications. Incomplete healing between
treatment sessions was associated with incomplete EIM. NSAID use, prior anti-reflux surgery, and
a history of erosive esophagitis predicted stricture formation.
Keywords
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Introduction
The goal of endoscopic eradication therapy for Barrett’s esophagus (BE) is to eliminate
dysplasia and intestinal metaplasia to prevent neoplastic progression to esophageal
adenocarcinoma. Recent guidelines recommend endoscopic eradication therapy with
radiofrequency ablation (RFA) and/or endoscopic mucosal resection (EMR) for treatment of
patients with BE and high-grade dysplasia (HGD).1 Further, “RFA should also be a
therapeutic option for treatment of patients with confirmed low-grade dysplasia (LGD) in
Barrett’s esophagus.”1
Although there is no consensus on whether all subjects with LGD should be treated with
RFA, the guidelines advocate for shared decision making based upon a discussion of risks
and benefits between the physician and patient. Despite the emerging role of RFA in the
treatment of neoplastic BE (LGD, HGD, and intramucosal carcinoma [IMC]), limited data
are available regarding the safety and efficacy of RFA in this cohort. No reports detail the
efficacy of RFA for treatment of IMC. Additionally, risk factors for incomplete eradication
of intestinal metaplasia, as well as risk factors for stricture formation following treatment,
are poorly understood.
We performed a retrospective study to assess the safety and efficacy of RFA for the
treatment of neoplastic Barrett’s esophagus in 244 patients: 53 with LGD, 152 with HGD,
and 39 with IMC. Additionally, we analyzed factors associated with complete eradication of
intestinal metaplasia (CEIM) and stricture formation.
Methods
Data collection and patient eligibility
We performed a retrospective study of consecutive patients with BE and confirmed
neoplasia (LGD, HGD, IMC) treated with RFA at University of North Carolina (UNC)
Hospitals between 2006 and 2011. To identify all such subjects at our institution, we
searched our electronic endoscopic database (ProvationMD, Wolters Kluwer, Minneapolis,
MN) from January 1, 2006 through November 1, 2011 using the following terms: Barrett,
esophageal adenocarcinoma, cancer, carcinoma in situ, dysplasia, ablation, radiofrequency.
We also searched for procedure codes foresophagoscopy with ablation (CPT 43228).
Each subject was reviewed by one of two investigators (WB, HK) using the electronic
medical record (WebCIS, University of North Carolina Health Care System) to determine
eligibility for inclusion. All institutional health information plus imported external records
were reviewed. Subjects were excluded if they never had treatment with RFA, were treated
with RFA for a non-BE related disease, or did not have neoplastic BE. All subjects with
neoplastic BE treated with RFA were studied for safety outcomes (safety cohort). The
efficacy analysis was restricted to exclude patients receiving ongoing RFA therapy as of
November 1, 2011.
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Pertinent data were extracted from clinical, endoscopy, and pathology reports for each
subject, including: demographic information (age, gender, race, body mass index), medical
and social history (erosive esophagitis, peptic stricture, alcohol/tobacco use), medication use
(antisecretory therapy, non-steroidal anti-inflammatory use), pre-treatment histology,
endoscopy findings (Prague C and M class, presence of ulcer, esophagitis or nodule),
treatment provided, ablation outcomes, and complications. To standardize methodology, the
first ten subjects were reviewed by both investigators jointly with discrepancies in data
collection resolved by consensus. For additional quality control, every 20th study subject
was reviewed independently by both investigators to assess inter-rater agreement.
Pre-treatment evaluation and procedural protocol
All patients had an initial consultation visit to discuss BE and dysplasia, its risk of
progression to cancer, and the risks and benefits of various treatment strategies. Prior to the
visit, the worst histologic grade of BE was determined by review of original pathology
reports. In all cases, review of pathology slides by a second expert gastrointestinal
pathologist was performed as part of the patient’s routine care, and if findings were
discordant, by an additional expert gastrointestinal pathologist for categorization.
Patients with BE and LGD were offered RFA plus endoscopic surveillance or endoscopic
surveillance alone. Patients with BE and HGD or IMC were offered RFA plus endoscopic
surveillance, esophagectomy, or endoscopic surveillance alone. Cases with lymphatic or
vasoinvasive tumor growth or poor tumor differentiation were not considered for curative
RFA therapy. Patients with HGD or IMC who elected for RFA had pre-treatment staging by
upper endoscopy (EGD) and endoscopic ultrasound (EUS) to identify findings of advanced
disease that would preclude curative endoscopic treatment (submucosal infiltration, lymph
node or metastatic spread). Patients with nodular disease had endoscopic mucosal resection
(EMR) using either the Olympus 18 mm oblique cap kit (Olympus America, Center Valley,
PA), or the Duette device (Cook Medical, Winston-Salem, NC). All EMRs performed with
the Olympus system were performed after submucosal injection of saline, while Duette
EMR was performed without prior injection. Any residual nodularity due to lateral extension
of the IMC was excised at subsequent examination. EMR of non-nodular mucosa was not
performed. RFA was performed 2 months after the final EMR, provided the pathology
specimen did not have submucosal involvement of carcinoma, and that the mucosa after
EMR demonstrated no residual nodularity. Twice daily proton pump inhibitor therapy was
prescribed prior to and throughout the endoscopic therapy period.
Radiofrequency ablation was performed using the HALO360 (circumferential) and HALO90
(focal) devices developed by BÂRRX Medical (Sunnyvale, CA). Standard procedural
technique was used.2 After primary circumferential ablation, patients had repeat upper
endoscopy every 2 months to assess response to treatment. Nodular BE was treated with
EMR. Residual, non-nodular BE was treated with focal ablation. Circumferential treatment
of the Z-line was performed using the HALO 90 device as a part of all focal treatment
sessions. Patients with visible breaks in the esophageal mucosa during treatment were
considered to have incomplete healing between treatment sessions, and were treated with
intensification of acid suppressive therapy. If no visible BE was present on white-light
endoscopy and narrow-band imaging, four-quadrant biopsies were performed in the tubular
esophagus with large capacity forceps every 1 cm spanning the entire original length of the
BE segment and extending to the top of the gastric folds. If these biopsies demonstrated no
persistent BE, treatment was considered complete, and the patient entered into endoscopic
surveillance. Treatment could be terminated prior to complete eradication of intestinal
metaplasia (CEIM), either at the request of the patient, or if, in the physician’s judgment, no
further progress was made in inducing neosquamous epithelium.
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Outcomes and statistical analysis
All biopsy specimens were reviewed by an expert gastrointestinal pathologist to determine
the presence of residual BE and degree of dysplasia. Efficacy outcomes included complete
eradication of intestinal metaplasia (CEIM), complete eradication of dysplasia (CED), RFA
treatment sessions, and total treatment sessions. CEIM was defined as complete endoscopic
resolution on white-light endoscopy and narrow-band imaging, as well as the absence of
intestinal metaplasia from all histologic specimens. CED was defined as the absence of
dysplasia from all histologic specimens. Total treatment sessions include any ablation or
endoscopic resection treatment. Primary safety outcomes included deaths, perforations,
strictures, bleeding, and hospitalizations. A stricture was defined as any narrowing of the
esophageal lumen requiring dilation. Bleeding was considered clinically significant if it
required hospitalization or a blood transfusion.
Efficacy outcomes are reported per protocol (PP) and on an intention-to-treat (ITT) basis.
Patients who were lost to follow-up, were diagnosed with an unrelated life-threatening
comorbidity that precluded further treatment, or died of an unrelated event during the
treatment period were included as treatment failures for the ITT analysis, but were excluded
from the PP analysis.
Patient characteristics associated with incomplete elimination of intestinal metaplasia and
stricture formation were assessed by comparing patients with these outcomes to those
without using non-parametric statistics (Fisher’s exact test for categorical variables,
Wilcoxon rank sum test for continuous variables). Bivariable comparisons were made for
age, gender, body mass index, pre-treatment histology, NSAID use, medium or larger hiatus
hernia, length of Barrett’s segment, presence of nodular disease, EMR during treatment,
incomplete healing between treatment sessions, and number of treatment sessions. The
characteristics most strongly associated with incomplete elimination of intestinal metaplasia
and stricture formation were included in a multivariable logistic regression model to
determine independent predictors of these outcomes. Given the limited number of patients
with incomplete elimination of intestinal metaplasia and stricture, we restricted our
multivariable model to avoid overfitting.
Among patients that achieved complete elimination of intestinal metaplasia, we plotted the
number of RFA treatment sessions to CEIM. Characteristics independently predictive of the
number of RFA sessions to eliminate intestinal metaplasia were assessed in a linear
regression model. Each of the characteristics assessed in the bivariable comparisons
described above were included in this model. Statistical significance was defined as a p-
value less than 0.05.
Results
Patient Eligibility
A total of 286 patients received EGD with ablative therapy at UNC Hospitals between 2006
and 2011. Of these patients, 42 were excluded: 19 never received RFA and were treated with
a different ablative modality (15 cryoablation, 2 argon plasma coagulation, 2 photodynamic
therapy); 5 were treated for a non-BE related disease (3 squamous cell carcinoma, 1 gastric
antral vascular ectasia, 1 gastric cardia dysplasia); and 18 had pre-ablation histology other
than LGD, HGD or IMC (11 nondysplastic BE, 7 invasive adenocarcinoma). The remaining
244 patients with LGD, HGD or IMC treated with RFA at UNC were included in the safety
analysis.
An additional 34 patients were receiving ongoing RFA therapy as of November 1, 2011 and
were excluded from the efficacy analysis. The remaining 210 patients were included in the
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intention-to-treat efficacy analysis. Within this cohort, 22 patients did not complete
treatment and were considered treatment failures: of these 22, 14 were lost to follow-up, 6
were diagnosed with an unrelated life-threatening comorbidity that halted further treatment,
and 2 died of an unrelated event during the treatment period. These 22 patients were
excluded from the per protocol analysis. The 14 subjects lost to follow-up did not differ
significantly from the remainder of the cohort with respect to pre-treatment histology or
median number of treatment sessions.
RFA Efficacy and Characteristics Associated with CEIM
Among 210 patients analyzed for efficacy (ITT), there were 44 with LGD, 135 with HGD,
and 31 with IMC. Most patients were Caucasian men, and on average, patients were 64
years old with a BMI of 29.7 kg/m2. Baseline characteristics of these patients are
summarized in Table 1.
Overall, patients with dysplastic BE or early cancer had CED in 87% (97% PP) and CEIM
in 80% (89% PP; Table 2). Complete treatment of BE required 3.3 ± 1.8 total treatment
sessions on average, of which 2.8 ± 1.7 were RFA treatment sessions (the remainder
represented EMR sessions). Circumferential ablation was performed in 126 of 210 patients
(60%), with 120 of these 126 patients receiving just one circumferential treatment. EMR
was performed in 69 of 210 patients (33%), with 58 of 69 having one endoscopic resection.
Four patients experienced disease progression during the study period despite RFA
treatment. Three patients with pre-ablation HGD progressed to IMC (n=1) and EAC (n=2),
and underwent successful treatment with esophagectomy. The fourth patient had pre-
ablation IMC that progressed to EAC. He underwent chemotherapy and radiation, and
subsequently opted for esophagectomy for a proximal stage Ia lesion and a distal stage IIb
lesion.
RFA was effective at eliminating intestinal metaplasia and dysplasia for all histologic grades
of dysplastic BE and early cancer. CED was achieved in 93% with LGD (100% PP), 84%
with HGD (97% PP), and 87% with IMC (93% PP). CEIM was achieved in 86% with LGD
(93% PP), 79% with HGD (90% PP), and 77% with IMC (83% PP). LGD and HGD
required approximately 3 total treatmentsessions to complete therapy (LGD 3.2 ± 1.9, HGD
3.1 ± 1.6) while IMC required an average of 4.1 ± 2.4 total treatment sessions to complete
therapy. The difference in total treatment sessions between IMC and dysplastic BE was due
to the increased number of EMRs necessary in the IMC group; EMR was performed at least
once in 87% of patients with IMC (27/31) compared to 28% of patients with HGD (38/135)
and 9% of patients with LGD (4/44). The total number of RFA sessions to complete therapy
did not differ by pre-treatment histology (LGD 3.0 ± 2.0, HGD 2.7± 1.5, IMC 2.9 ± 2.0).
Intestinal metaplasia was not completely eradicated in 20 of 188 (10.6%) patients in the per
protocol analysis (Table 3). Compared to patients who achieved CEIM, patients with
incomplete eradication of BE were: 1) more likely to be female (40% vs 20%, p=0.045); 2)
had greater length of BE (5.5 vs. 4.0 cm, p=0.03); 3) were more likely to have incomplete
healing between treatment sessions (45% vs 15%, p=0.004); and 4) required more total
treatment sessions to complete therapy (median 4.0 vs 3.0, p=0.007). Interestingly, pre-
treatment histology was not a predictor of incomplete EIM. Although rates of CEIM did
differ numerically by pre-treatment histology (Table 2), these differences did not reach
statistical significance (p for trend=0.20). Also, age, body mass index, or the presence of
nodular BE at baseline were not significantly associated with achieving CEIM. Incomplete
healing between treatment sessions, length of BE and number of treatment sessions were
most strongly associated with incomplete EIM on bivariable analysis. Therefore, these three
variables were included in our logistic regression analysis. After performing multivariate
analysis, incomplete healing between treatment sessions (OR 3.7; 95% CI 1.3–9.9) was an
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independent predictor of incomplete EIM after controlling for length of BE and total number
of treatment sessions to complete therapy.
CEIM was achieved in more than half of patients after 3 RFA sessions and 75% after 4
sessions (Figure 1). The number of RFA sessions to achieve CEIM was independently
associated with the length of the Barrett’s segment (p<0.001). The predicted number of
treatment sessions for patients with 2-, 5-, and 8cm of Barrett’s was 2.1, 2.7 and 3.4,
respectively (Figure 2). On average, about one additional treatment session was necessary
for each 5cm of Barrett’s. Patients with nodular disease required 0.8 less RFA sessions
(p=0.02), although the total treatment sessions did not differ due to the need for EMR in
these patients. Patients with incomplete healing between treatment sessions required 0.6
more RFA sessions (p=0.02). Age, gender, BMI, NSAID use, hernia size, and pre-treatment
histology were not associated with the number of sessions to achieve CEIM.
RFA Safety and Characteristics Associated with Stricture
Among 244 patients analyzed for safety, there were 53 with LGD, 152 with HGD, and 39
with IMC. On average, patients were 65 years old, most were Caucasian (6 African-
American), most were men (192/244, 79%), and the average body mass index was 29.6 kg/
m2. Patients had a median length of BE of 4 cm (IQR: 2 – 7) and 30% had nodular BE at
baseline (73/244). Overall, 110 EMR treatments and 667 RFA treatments (158
circumferential, 509 focal) were administered (777 total treatment sessions). There were 94
patients treated with EMR (39%), of which 78 had one EMR treatment (83%), and 16 had
two treatments. There were 146 patients treated with circumferential ablation (60%), of
which 139 had one circumferential RFA treatment (95%). Patients had an average of 3.2 ±
1.9 total treatment sessions, including 2.7 ± 1.7 RFA treatment sessions.
Complications occurred in 24 of 244 patients (9.8% of patients, 3.1% of procedures) (Table
4). There were no deaths or esophageal perforations. Most complications were strictures,
which occurred in 20 patients (8.2% of patients, 2.6% of procedures) after a median of 63
days after initial treatment. Two of these strictures occurred after EMR, and the other 18
after RFA. All but one of the strictures were detected on routine follow-up endoscopy and
most were free of dysphagia. Stricture rates did not different significantly based upon
histology, occurring in: 6/53 with LGD (11.3%), 9/152 with HGD (5.9%) and 5/39 with
IMC (12.8%). All strictures were < 1 cm in length, and resolved after a median of 1
endoscopic dilation (maximum of 4 dilations). Four of the 20 patients (20%) had stricture
recurrence noted on a subsequent endoscopy, and 3 of these patients required an additional
endoscopic dilation. Post-procedural hemorrhage occurred in four patients (1.6% of patients,
0.5% of procedures), with 2 occurring after EMR and 2 occurring after RFA. In each case,
the bleeding was noted during the endoscopy and treated with injection of epinephrine at the
bleeding site plus either hemostatic clips (3 of 4) or bipolar cauterization (1 of 4). All four of
these patients were subsequently hospitalized, with 1 patient receiving transfusion. Three of
these four were discharged the next day, and the last had a hospitalization of 2 days. There
were no other hospitalizations.
The characteristics of patients with and without stricture during treatment are listed in Table
4. Compared to patients who did not develop a stricture, patients who developed a stricture
were more likely to: 1) use NSAIDs (70% vs. 45%, p=0.04); 2) have had antireflux surgery
before treatment (15% vs. 3%, p=0.04); and 3) have a history of prior erosive esophagitis
(35% vs. 12%, p=0.01). Although not statistically significant (p>0.05), patients with
stricture were more frequently female (35% vs. 20%), had incomplete healing between
treatment sessions (35% vs. 17%), and had an EMR after RFA treatment initiation (20% vs.
9%). Stricture was not statistically associated with pre-treatment histology, although patients
with stricture were numerically more likely to have IMC before treatment (25%) compared
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to those without stricture (15%). The three variables associated with stricture formation on
bivariable analaysis were included in our multivariate analysis. NSAID use (OR 3.1; 95%CI
1.1–8.7), prior antireflux surgery (OR 6.6; 95%CI 1.5–29.6), and a history of prior erosive
esophagitis (OR 3.7; 95%CI 1.3–10.5) were all independent predictors of stricture
formation.
Discussion
The outcomes of treatment of neoplastic BE with RFA are not well-described, nor are risk
factors for complications or incomplete eradication. This study reports our experience
treating 244 patients with neoplastic BE using RFA. We found that RFA was highly
effective at eradicating dysplasia and intestinal metaplasia, with at least 77% CEIM (83%
PP) and 84% CED (93% PP) regardless of degree of dysplasia or the presence of IMC. Male
gender, shorter length of BE, and complete healing of the mucosa between treatment
sessions were associated with CEIM, with complete healing of the mucosa being an
independent predictor of CEIM. Length of the Barrett’s segment, presence of nodularity, and
incomplete healing independently predicted the number of RFA treatments to achieve
CEIM. Complications occurred in roughly 10% of patients, with most being benign
strictures that were amenable to endoscopic dilation. History of prior erosive esophagitis,
NSAID use, and previous Nissen fundoplication were independent predictors of stricture
formation.
Published reports of the efficacy and safety of RFA for neoplastic BE are heterogeneous.
Reported rates of complete eradication of intestinal metaplasia (CEIM) vary from 54–100%
for HGD and 71–100% for LGD.3 Similarly, published rates of stricture and bleeding vary
from 0–8% and 0–10%, respectively.3 Prior to the present study, the largest reported cohort
of patients treated with RFA for neoplastic BE was an early report of a multicenter registry
of 142 patients with HGD enrolled at 16 institutions.4 In contrast to the present study, CEIM
was achieved in just 54% of patients in that study; however patients received only
circumferential RFA, as the focal RFA device was not yet developed. In the randomized,
sham-controlled AIM Dysplasia Trial, 42 patients with LGD and 42 patients with HGD
received up to 4 RFA treatment sessions over the course of 9 months. Biopsies taken at 12
months showed CEIM in 74% with HGD and 81% with LGD, response rates slightly lower
than the current report.5 Of note, this study restricted the number of treatments to four, and a
subsequent report noted that further treatment resulted in additional cases of CEIM.6
Several findings of our study merit mention. This study identified incomplete mucosal
healing between treatment sessions as an independent predictor of incomplete eradication of
intestinal metaplasia. Incomplete healing may be a marker of incompletely controlled reflux
disease, despite the high dose (twice daily) proton pump inhibitor therapy used in thispatient
population. Previous work has demonstrated that a substantial minority of subjects with BE
continue to experience pathological reflux, even with chronic high dose PPI therapy.7, 8
Although this explanation seems tenable, the lack of routine pH testing in this population in
the current study makes us unable to comment on the potential role of inadequate acid
suppression in subjects with incomplete eradication in this study.
Other findings of note were that combined treatment with EMR and RFA was effective for
the treatment of IMC (77% CEIM, 87% CED) in the 31 patients reported here. Previous data
from smaller series did not assess the efficacy of RFA specifically for subjects who had
developed IMC.9 Of note, 24 of 31 patients with IMC had nodular disease and were treated
with pre-RFA EMR, excising all nodular IMC prior to treatment with RFA. Also, our study
assessed the risk factors for stricture development with therapy. Previous studies attempting
to do so had inadequate power to identify any predictors, due to small sample size and the
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limited number of patients with stricture formation.10 Interestingly, in the present study,
NSAID use was associated with an increased likelihood of stricture formation. Some
clinicians might consider routine administration of NSAIDs or aspirin to BE patients due to
the large body of epidemiological data suggesting a protective effect of NSAIDs and aspirin
on the development of esophageal cancer.11 These data suggest that this practice might not
be advisable during attempts at endoscopic ablation, perhaps due to direct mucosal injury
from these medicines.
There are several strengths to our study. This study represents the largest published cohort of
patients with neoplastic BE treated with RFA. Biopsy samples were analyzed by expert
gastrointestinal pathologists, with all dysplasia confirmed by 2 readings. Our study
definitions were conservative, counting any subject as a treatment failure in intention-to-
treat analysis if therapy was halted for any reason prior to eradication of dysplasia or
intestinal metaplasia. Our study also had several limitations. One limitation is that this study
was conducted at a tertiary-care referral center. Endoscopies and interventions were
performed by the same experienced gastroenterologists. Therefore, whether or not these
results can be generalized to community practice settings is unknown. The limited number
of incomplete responders in this study, as well as our relatively small numbers of
complications, may have limited our ability to detect independent predictors of incomplete
eradication or stricture formation in our multivariate analysis. For example, longer segment
length seems intuitive as a proxy for burden of disease, and has been suggested as a
predictor of incomplete response in previous work.12 Finally, despite our rigorous attempts
at complete collection of data, the retrospective nature of this study makes underestimation
of complications or misclassification errors possible.
In summary, RFA is a safe and effective treatment option for patients with BE with LGD,
HGD or IMC. CEIM was achieved in at least 77% of patients regardless of degree of
dysplasia. Patients with complete healing of their mucosa between treatment sessions are
more likely to have CEIM and length of the Barrett’s segment predicts the number of RFA
treatments that will be required. Complications occurred in around 10% of patients, most of
which were benign strictures that were amenable to endoscopic dilation. Patients who used
NSAIDs, have a history of prior erosive esophagitis, or those who had a previous surgical
antireflux procedure were more likely to have a stricture. The findings of this study can be
used to inform treatment decisions and appropriately counsel patients with neoplastic BE
being considered for treatment with RFA.
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BE Barrett’s esophagus
CED complete eradication of dysplasia
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EMR endoscopic mucosal resection
EUS endoscopic ultrasound
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Number of treatment sessions to eliminate intestinal metaplasia.
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Figure 2. Predicted number of treatment sessions to achieve CEIM by Prague M length
*
* - Adjusted for age, gender, body mass index, NSAID use, presence of nodular disease,
incomplete healing during treatment, medium or large hiatal hernia, and advanced histology
(HGD, IMC).
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Table 2
Eradication rates, based on pre-treatment histological stage of disease
Per protocol, n (%) Intention-to-treat, n (%)
Any histology
 N 188 210
 CED 182 (97) 182 (87)
 CEIM 168 (89) 168 (80)
 Total treatment sessions, mean (SD) 3.2 (1.7) 3.3 (1.8)
 RFA treatment sessions, mean (SD) 2.7 (1.5) 2.8 (1.7)
 Low-grade dysplasia
  N 41 44
  CED 41 (100) 41 (93)
  CEIM 38 (93) 38 (86)
  Total treatment sessions, mean (SD) 3.0 (1.6) 3.2 (1.9)
  RFA treatment sessions, mean (SD) 2.8 (1.7) 3.0 (2.0)
 High-grade dysplasia
  N 118 135
  CED 114 (97) 114 (84)
  CEIM 106 (90) 106 (79)
  Total treatment sessions, mean (SD) 3.1 (1.5) 3.1 (1.6)
  RFA treatment sessions, mean (SD) 2.7 (1.3) 2.7 (1.5)
 Intramucosal carcinoma
  N 29 31
  CED 27 (93) 27 (87)
  CEIM 24 (83) 24 (77)
  Total treatment sessions, mean (SD) 4.0 (2.4) 4.1 (2.4)
  RFA treatment sessions, mean (SD) 2.9 (1.9) 2.9 (2.0)
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Table 3
Comparison of subjects attaining complete eradication of intestinal metaplasia to those who did not
Characteristic
Elimination of Intestinal Metaplasia
p-valueIncomplete (n=20) Complete (n=168)
Age, yrs (IQR) 67.7 (56.8, 77.8) 64.0 (57.2, 71.6) 0.24
Male (n) 60% (12) 80% (134) 0.045
Body mass index, kg/m2 (IQR) 31.6 (27.2, 35.6) 29.3 (25.8, 33.5) 0.24
Pre-treatment histology (n)
 LGD 15% (3) 23% (38)
0.20* HGD 60% (12) 63% (106)
 IMC 25% (5) 14% (24)
NSAID use (n) 50% (10) 51% (86) 0.92
Medium or larger hiatus hernia (n) 65% (13) 56% (94) 0.48
Length of BE, cm (IQR) 5.5 (3.5, 8.5) 4 (1, 6) 0.03
Nodular BE (n) 30% (6) 29% (48) 1.00
EMR during treatment (n) 45% (9) 35% (59) 0.32
Incomplete healing between treatment sessions (n) 45% (9) 15% (26) 0.004
Total treatment sessions (IQR) 4 (3,5) 3 (2,4) 0.007
RFA treatment sessions (IQR) 3 (2,4) 2 (2,3) 0.11
Treatment days (IQR) 227 (127, 301) 126 (63,218) 0.03
*
p-value for trend
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Table 4
Comparison of subjects developing stricture to those who did not
Characteristic Stricture (n=20) Stricture-Free (n=224) p-value
Age, yrs (IQR) 64.1 (61.3,69.2) 65.4 (57.3,72.6) 0.63
Male (n) 65% (13) 80% (179) 0.15
Body mass index, kg/m2 (IQR) 29.0 (26.9,35.4) 29.0 (25.8,33.0) 0.53
History of prior stricture (n) 15% (3) 4% (9) 0.06
History of prior erosive esophagitis (n) 35% (7) 12% (27) 0.01
Pre-treatment histology (n)
 LGD 30% (6) 21% (47)
0.20 HGD 45% (9) 64% (143)
 IMC 25% (5) 15% (34)
NSAID use (n) 70% (14) 45% (100) 0.04
Medium or larger hiatus hernia (n) 65% (13) 58% (224) 0.64
Intact Nissen fundoplication (n) 15% (3) 3% (7) 0.04
Length of BE, cm (IQR) 5 (2,6.5) 4 (2,7) 0.74
Nodular BE (n) 25% (5) 30% (68) 0.80
EMR during treatment (n) 20% (4) 9% (21) 0.62
Incomplete healing between treatment sessions (n) 35% (7) 17% (37) 0.06
Total treatment sessions (IQR) 3 (2,5) 3 (2,4) 0.09
RFA treatment sessions (IQR) 3 (1,4) 2 (1,3) 0.36
Treatment days (IQR) 154 (98,262) 123 (61,228) 0.16
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